Tysabri and Progressive Multifocal Leukoencephalopathy: What Patients Need to Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Pharmaceutical Risks

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This condition, though rare, is a serious brain infection associated with the medication. Building on decades of pharmacovigilance research, this page explains what PML is, how it relates to Tysabri, and what to watch for.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most serious safety alert, due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically leads to death or severe disability, and the warning emphasizes that healthcare professionals must monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable but often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain imaging, typically magnetic resonance imaging (MRI), and detection of JC virus DNA in cerebrospinal fluid. The condition is usually fatal or results in severe, permanent disability.

Risk Factors and Mechanisms of PML in Tysabri Patients

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration from the bloodstream into tissues, including the central nervous system. This immunosuppressive effect reduces normal immune surveillance in the brain, allowing latent JC virus to reactivate and cause PML. Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and those with all three risk factors face the greatest likelihood of developing PML. In clinical trials, PML occurred in three patients who received Tysabri: two among 1,869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1,043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight the potential for PML to develop even within the first year of treatment.

Regulatory Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML has been a subject of regulatory and legal scrutiny. The boxed warning explicitly states that Tysabri increases the risk of PML and that risk factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients and prescribers are aware of the PML risk and that monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients have developed PML, leading to litigation and settlement considerations. For affected patients in Florida, legal claims may focus on whether the warnings were sufficient to inform patients and healthcare providers of the true magnitude of risk, and whether the benefits of Tysabri were adequately weighed against the potential for catastrophic harm.

Settlement Considerations for Florida Patients

Settlement-related considerations for patients who develop PML after Tysabri exposure often involve the timeline between drug administration and documented harm. PML can occur months to years after starting Tysabri, with risk increasing over time. The boxed warning notes that longer treatment duration, especially beyond two years, is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In legal contexts, establishing a clear temporal relationship between Tysabri use and PML diagnosis is critical. Medical records documenting the start of Tysabri therapy, any prior immunosuppressant use, anti-JCV antibody status, and the date of PML symptom onset or diagnosis are essential evidence. Settlements may account for medical expenses, lost income, pain and suffering, and long-term care needs, given the severe and often permanent nature of PML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has assigned a boxed warning due to this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with all three factors face the highest risk.

What legal options are available for Florida patients who developed PML after Tysabri?

Florida patients may pursue claims focusing on inadequate warnings or failure to weigh risks. Settlements can cover medical expenses, lost income, pain and suffering, and long-term care. Establishing a clear timeline between Tysabri use and PML diagnosis is crucial.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.